56 results about "MMP Inhibitors" patented technology

The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.

A compound selected from those of formula (I): in which:W represents N or C—R1; in which R1 is as defined in the description,X represents N or C—R2 in which R2 is as defined in the description,Y represents a group selected from oxygen, sulfur, —NH, and —Nalkyl,Z represents a group selected from oxygen, sulphur, —NR8 in which R8 is as defined in the description, and optionally carbon depending the definition of Y,n is an integer from 0 to 8 inclusive,Z1 represents a group —CR9R10 wherein R9 and R10, are as defined in the description, which group contains optionally multiple bonds or heteroatomes,A represents a cyclic group,m is an integer from 0 to 7 inclusive,the group(s) R4 is (are) as defined in the description,R3 represents a group selected from hydrogen, alkyl, alkenyl, alkynyl, and the group of formula: in which p, Z2, B, q, and R13 are as defined in the description,optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.

The present invention is directed to a compound of formula (1), wherein R1, R2, R3, R4, A, L and n are as defined herein, its pharmaceutical composition, preparation and uses as a MMP inhibitor.

Disclosed is a coated suture thread comprising a matrix formed by an immobilized and crosslinked plurality of fibrinogen layers into and / or onto which one or several pharmacological substances that inhibit tissue break-down, such as MMP inhibitors and / or corticosteroids and / or COX inhibitors, are attached and / or associated. Further, a method of producing such a coated suture thread as well as the use thereof for suturing damaged tissue, such as damaged tendon, ligament, intestine and / or skin, are described.

A topical composition according to the present invention for use in a skin care regimen that provides matrix metalloprotease (MMP) inhibiting activity, tissue inhibitor of metalloprotease (TIMP) inducing activity, and immediate and delayed antioxidative activity. Preferably, the topical composition comprises at least one MMP inhibitor, a TIMP inducing agent, Tremella fuciformis (snow fungus) extract, Camellia sinensis (green tea) leaf extract, and Eugenia caryophyllus (clove) extract. The compositions are useful in anti-wrinkle and anti-aging products, providing elasticity, firmness, tone and texture to the skin, ameliorating fine lines and preventing skin damage.

Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the MT1-MMP cytoplasmic domain is capable of inhibiting MT1-MMP in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease.

Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the MT1-MMP cytoplasmic domain is capable of inhibiting MT1-MMP in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease.

The present invention is directed to a compound of formula (I) wherein R1, R2, R3, R4, A, L and n are as defined herein, or a pharmacologically acceptable salt thereof, its pharmaceutical composition and it use as a MMP inhibitor.

The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestinal operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and / or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and / or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.

The present invention is in the field of personal care compositions, in particular relates to skin lightening compositions. A composition that combines the cyclic adenylic acid reduction and the reduction of melanin content in melanocytes remains to be desired. It has been found that niacinamide in combination with MMP inhibitor galardin synergistically reduces melanin content in melanocytes. The invention thus relates to a composition comprising a synergistic combination of niacinamide and galardin for use in skin lightening. Thus the composition, when applied topically over an appropriate length of time in-vivo, may be used to lighten the skin, or to reduce age spots or freckles.

The present invention is directed to a compound of formula (I),wherein R1, R2, R3, R4, A, L and n are as defined herein, its pharmaceutical composition, preparation and uses as a MMP inhibitor.

The present invention is in the field of personal care compositions; in particular skin lightening compositions. A more effective way to reduce melanin content in melanocytes remains to be desired. It has been found that 4-hexylresorcinol in combination with MMP inhibitor galardin synergistically reduces melanin content in melanocytes. The invention thus relates to a composition comprising a synergistic combination of 4-hexylresorcinol and galardin for use in skin lightening. Thus the composition, when applied topically over an appropriate length of time in-vivo, may be used to lighten the skin, or to reduce age spots or freckles.